ANI Pharmaceuticals to present Phase 4 SYNCHRONICITY trial data on fluocinolone acetonide intravitreal implant at AAO 2026 meeting

By Public Technologies
  • ANI Pharmaceuticals announced upcoming presentations of Phase 4 data for its fluocinolone acetonide intravitreal implant at AAO 2026.
  • SYNCHRONICITY trial results in chronic non-infectious posterior uveitis will be presented Oct. 9, 2026 in a late-breaking oral session.
  • Management highlighted prior disclosure of six-month topline results in July 2026, with additional findings set for the AAO update.
  • Post-hoc NEW DAY analyses in diabetic macular edema will be released as an on-demand ePoster, comparing outcomes in rescued versus non-rescued patients.
  • Company also scheduled an encore podium presentation of SYNCHRONICITY results at Hawaiian Eye & Retina on Jan. 21, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300655PRIMZONEFULLFEED9836269) on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk